SMN1 and proximal spinal muscular atrophy: The antisense oligonucleotide nusinersen modifies the pre-mRNA splicing of the survival motor neuron gene SMN2 which leads to increased production of full-length SMN protein, thereby compensating for the genetic defect in the SMN1 gene and improving motor function in patients with different SMA phenotypes (3–5).